BioVie Inc - Ordinary Shares - Class A
BIVI
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.14M
Close$
$3.92
140.8% upside
Current Fair Value
140.8% upsideUndervalued by 140.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.14 Million |
|---|---|
| Enterprise Value | $3.44 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.05 |
| Beta | 0.67 |
| Outstanding Shares | 7,542,638 |
Return
| Return on Equity | -215.34% |
|---|---|
| Return on Assets | -155.20% |
| Return on Invested Capital | -213.28% |
Valuation & Multiples
| P/E Ratio | -0.5 |
|---|---|
| PEG | -0.81 |
| Price to Sales | - |
| Price to Book Ratio | 1.63 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.15 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-0.52
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 20.31%▲ 6.65% |
|---|---|
| Total Invested | $2.86M▲ 97.99% |
| Investors Holding | 36▲ 4.00% |
ESG Score
No data
About BioVie Inc
3 employeesBioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of market exclusivity i...